Management of fatigue in persons with multiple sclerosis
- 1Department of Rehabilitation Medicine, Royal Melbourne Hospital, Melbourne, VIC, Australia
- 2The University of Melbourne, Melbourne, VIC, Australia
- 3School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia
Fatigue is one of the most common symptoms of multiple sclerosis. Despite advances in pharmacological and non-pharmacological treatment, fatigue continues to be the disabling symptom in persons with MS (pwMS), affecting almost 80% of pwMS. In current practice, both pharmacological and non-pharmacological interventions are used in combination, encompassing a multi-disciplinary approach. The body of research investigating the effect of these interventions is growing. This review systematically evaluated the existing evidence on the effectiveness and safety of different interventions currently applied for the management of fatigue in person with multiple sclerosis in improving patient outcomes, to guide treating clinicians.
Multiple sclerosis (MS), a chronic progressive demyelinating disease of the central nervous system (CNS), is the commonest cause of chronic neurological disability in young adults (1, 2). It affects approximately 2.5 million persons worldwide and the prevalence of MS in Australia is estimated to be over 20,000 (95.2 per 100,000) persons (2, 3). MS is complex and the exact pathogenesis is unclear. Fatigue is one of the most common symptoms of MS, affecting almost 80% of persons with MS (pwMS) (2), with 55% of pwMS describing it as one of the worst symptoms they experience (1). Fatigue is defined as “a subjective lack of physical or mental energy that is perceived by the individual or caregiver to interfere with usual and desired activities” (4). The definitive cause of fatigue in MS is currently unknown, however, it is postulated that MS-related fatigue may result from centrally mediated processes characterized by MS itself, such as demyelination and axonal loss in the CNS or immune actions (Primary fatigue) or from MS-related complications (trigeminal neuralgia, spasms, psychological issues, etc.), musculoskeletal problems (pain, posture, gait anomalies, etc.), sleep problems, and medications (Secondary fatigue) (5, 6). Experimental studies have shown that fatigue results from reduced voluntary activation of muscles by means of central mechanisms (5). In general, fatigue is a poorly defined construct and hence difficult to measure (7). The MS International Federation recognized two types of fatigue in pwMS, namely: physical or motor fatigue (muscle weakness, slurred speech, unable to perform daily tasks, etc.) and cognitive fatigue (deterioration of cognitive function such as, reduced reaction time response, alertness during the day, difficulty in thinking, concentration, memory, recall, word finding, etc.) (7, 8). Further, fatigue can be acute (newly occurring in the past 6 weeks) or chronic (lasting longer than 6 weeks) (4). Brañas et al. classifies fatigue experienced by pwMS into: “fatigability” (increased weakness with exercise or as the day progresses) and “lassitude” (abnormal constant and persistent sense of tiredness) (9). In contrast to fatigue in normal people, MS-related fatigue has distinctive characteristics, including: occurs on a daily basis; worse as day progresses; aggravated by heat and humidity; comes on more easily and suddenly; more severe than normal fatigue; and more likely to interfere with role performance and physical functioning (2, 9). Clinically, fatigue may manifest as exhaustion, lack of energy, increased somnolence, or worsening of MS symptoms and activity, and heat typically can exacerbate symptoms (6). The mechanism for fatigue in MS is not known and several different factors are believed to contribute to fatigue (Box 1).
Box 1. Primary and secondary factors in Multiple Sclerosis fatigue.
• Immune dysregulation – changes in neuroendocrine function.
• Central nervous system mechanisms – neuronal dysfunction due to immune injury, demyelination and inflammation, impaired innervation, and activation of muscle groups leading to compensatory increase in central motor drive exertion and more energy depletion.
• Endocrine factors – abnormalities in hypothalamic/pituitary/adrenal axis.
• Neurotransmitter dysregulation – dopaminergic, histaminergic, and serotonergic pathways may contribute to fatigue.
• Physical deconditioning from failure to get adequate exercise.
• Sleep dysfunction – may also be due to nocturnal spasms, pain, incontinence, and depression.
• Pain – sensory disturbances, neuralgia, dysesthesia, and spasms.
• Psychological factors – lack of self-efficacy may increase feelings of fatigue.
• Depression – closely related to poor sleep, pain, and fatigue.
• Medications – can worsen fatigue [antispasticity agents, e.g., Baclofen].
Fatigue is prevalent in the MS population and a significant health problem, adversely impacting on activities of daily living, ability to work, social life, and quality of life (QoL) (4). Fatigue has been associated with increased cognitive impairment and on a person’s participatory roles (such as relationships and social integration, etc.) (11). There is strong consensus in literature that many psychosocial factors influence adjustment to fatigue, including the family’s response, coping behaviors, psychological distress, and fatigue-related disability (1, 5). Fatigue is also associated with poorer general health, increased disability, and higher rates of health care utilization (12, 13). In a descriptive study of MS-related disability (n = 101), 81% reported fatigue, with those in higher fatigue grades reporting more disability and health care visits, and lower QoL (14). In another study (n = 656 patients), 22% reported limitation in level of physical activity, 14% stated it required them to have more frequent rest breaks, and 10% had to discontinue work due to fatigue (15).
Multiple sclerosis can have a fluctuating and often progressive course, making symptomatic management more challenging. The key to symptomatic management of pwMS, including fatigue, is achievement of individualized, patient-centered goals that are set collaboratively with patients, their carers, and the rehabilitation team in a functional context, and should be based on the medical and functional status of each patient (16–18). The quality and quantity of fatigue, and its impact on function is obtained in the patient assessment and history. All contributing factors to fatigue should be identified, and other non-MS causes should be excluded and/or treated appropriately (4). A number of instruments exist in MS literature for the assessment of fatigue and can be subjective (self-reported by patients) and objective (quantified by clinicians through various parameters) (10). Subjective or patient-reported instruments are specifically designed to incorporate a patient’s viewpoint and are more practical for use in clinical settings (10, 19). A list of commonly used subjective measures of MS-related fatigue is provided in Table 1.
The published National Institute for Clinical Excellence (NICE) clinical practice guidelines on the management of MS (26) highlights the significance of diagnosing and treating fatigue as part of the management plan. A clinical decision-making flowchart for managing fatigue in MS (10) is shown in Figure 1. Both pharmacological and non-pharmacological interventions individually or in combination are recommended for the management of fatigue in pwMS. Evidence supporting the efficacy of these interventions in MS-related fatigue is still ambiguous and insufficient (5, 9). The published guidelines acknowledge that the recommendations were mostly driven by the expert opinions rather than by high-quality research-derived evidence (26). Further, interventions for fatigue management in pwMS are still not prescribed in a systematic way (9).
Figure 1. Clinical decision-making flow chart for treating fatigue in MS. Adapted from MacAllister and Krupp (10).
The most commonly used agents for pharmacological treatment for fatigue in pwMS include amantadine, modafinil, and pemoline (9). The NICE guidelines (26) concluded that the efficacy of any pharmacological agents specifically to treat neurological fatigue is yet to be established. Many argue that non-pharmacologic approaches used in isolation and/or in combination with pharmacological agents are the mainstay in the management of fatigue in pwMS (9, 10). Non-pharmacological interventions may include education (e.g., avoid heat, use air conditioners, and cooling gel vests); address lifestyle factors (e.g., diet and exercise; avoid physical activity at midafternoon); pacing (regular rest breaks between activities); energy conservation and work simplification strategies (e.g., use of assistive devices, adaptive equipment, gait aids), and improve aerobic capacity and endurance (e.g., structured exercise programs).
Despite advances in pharmacological and non-pharmacological treatment, MS-related fatigue continues to be the common disabling symptom in pwMS. In current practice, both pharmacological and non-pharmacological interventions are used in combination, encompassing a multi-disciplinary approach. The body of research investigating the effect of these interventions on management of fatigue in MS is growing. The benefit and harms associated with most of these interventions in pwMS needs to be established comprehensively to guide treating clinicians. Therefore, the aim of this review is to systematically evaluate the existing evidence to investigate the effectiveness and safety of interventions for the management of fatigue in pwMS in improving patient outcomes.
An integrated approach was used, which included a comprehensive review of literature (peer review and gray literature) documenting interventions currently used in management of fatigue in MS. A comprehensive search of the literature published was undertaken till 6th June 2014 using Medline, Embase, PubMed, and Cochrane Library databases. The search strategy included interventional studies investigating management of fatigue in pwMS, using combinations of multiple search terms for three themes: MS, interventions (pharmacological and non-pharmacological), and fatigue. Medical subject heading (MeSH) search terms were used for all databases and a keyword search was used if the MeSH term was not available. The bibliographies of identified articles were scrutinized for additional references and a manual search of relevant journals was undertaken. A gray literature search using different internet search engines and websites such as: system for Information on Gray Literature in Europe; New York Academy of Medicine Gray Literature Collection, and Google Scholar, was also undertaken. Additional searches of the websites of prominent national and international organizations associated with MS management were conducted to identify relevant reports, health technology assessments, or other related materials.
Studies that compared various interventions in management of fatigue in pwMS with routinely available local services or lower levels of intervention or placebo, or studies that compared such interventions in different settings or at different levels of intensity, were included. All systematic reviews, meta-analyses, randomized clinical trials (RCTs), and controlled clinical trials (CCTs), quasi-randomized and quasi-experimental designs with comparative controls, and controlled before-and-after studies were included. Whenever RCTs/CCTs were lacking, a search for relevant observational studies was conducted. Studies involving other medical conditions, where data were specifically provided for MS-related fatigue, were also included. Descriptive studies and narrative reviews were explored to identify policies, protocols, and gaps in service provision. Where high-quality systematic reviews or meta-analyses were identified, articles published prior to the date of that review’s search strategy were excluded.
Limits placed included English-language publication and inclusion of adults aged 18 years and above. Theses, narrative reviews, editorials, case reports, economic evaluation, conference proceedings, and studies evaluating surgical intervention or diagnostic procedures for MS-related fatigue were excluded.
Two authors (Bhasker Amatya and Mary Galea) independently screened and shortlisted all abstracts and titles of studies identified by the search strategy for inclusion and appropriateness based on the selection criteria. Each study was evaluated independently by authors. If necessary, the full text of the article was obtained for further assessment to determine whether the article met the inclusion/exclusion criteria. If no consensus was reached regarding the possible inclusion/exclusion of any individual study, a final consensus decision was made by the third author (Fary Khan). Further information about the complete description of the interventions from the trialists was obtained, where necessary.
Data extraction was conducted by two authors independently, using a standard pro forma. The information obtained from all included studies was: publication date and country, study location, study design, intervention, outcome measures used, and fatigue-related outcomes. Any discrepancies were resolved by all authors re-reviewing the study.
Evidence for all included studies was categorized according to study design using a hierarchy of evidence in descending order and priority were given to the most recently published high-quality systematic reviews or meta-analysis and RCT. Formal levels of evidence were assigned using a standard format defined by National Health and Medical Research Council (NHMRC) pilot program 2005–2006 for intervention studies (Table 2) (27).
Table 2. Designations of “levels of evidence” according to type of research question (27) (intervention studies only).a
The electronic database search retrieved 1673 published articles on fatigue in MS; 428 articles met title inclusion criteria of which 55 articles met the abstract inclusion criteria and went on to full-text review. Four articles that met the abstract inclusion criteria were identified from the bibliographies of relevant articles. Overall, 27 studies (12 systematic reviews/meta-analyses, 12 RCTs, 2 CCT, and 1 comparative studies) fulfilled the inclusion criteria for this review. The study selection process is summarized in the PRISMA flow diagram shown in Figure 2.
Evidence for Pharmacological Interventions for Fatigue in Persons with MS
Currently, different pharmacological agents are used for treatment for fatigue in pwMS, which include amantadine, modafinil, and pemoline (9, 11). Modafinil, a “wake promoting” agent that selectively works in the hypothalamic pathways used in narcolepsy, has been reported to improve fatigue in progressive MS (5, 9). The efficacy of pemoline, a CNS stimulant, is still unclear (9, 28, 29). Amino pyridines (potassium channel blockers) and amantadine (N-methyl d-aspartate receptor antagonist) have been trialed; however, systematic reviews failed to find evidence for efficacy or safety for their use (30). There is empirical support for use of antidepressants in MS-related fatigue, as depression is considered to be one of the major contributing factors (31, 32).
A recently published comprehensive meta-analysis of different interventions (pharmacological and non-pharmacological) included seven RCTs evaluating different medications used for the management of fatigue in pwMS. The authors found weak and inconclusive beneficial effects of pharmacological intervention for MS-related fatigue, with small and non-significant pooled effect sizes (ESs) with a relatively narrow 95% CI (ES = 0.07, 95% CI: −0.22 to −0.37, p = 0.63) (11). The pharmacological agents in this review were restricted to Amantadine and Modafinil. Similar inconclusive and insufficient research-derived evidence to support the various pharmacological treatments was reported in another comprehensive systematic review of pharmacological interventions for MS-fatigue published previously (9). The authors systematically reviewed studies investigating only two pharmacological agents: amantadine and pemoline. The studies evaluating the effectiveness of amantadine (four RCTs) showed a pattern in favor of amantadine compared with placebo; however, there was considerable uncertainty about the validity and clinical significance of this finding. Studies investigating efficacy of pemoline (n = two RCTs) demonstrated no overall tendency in favor of pemoline over placebo (9). In addition, an excess of reports of adverse effects was noted for pemoline.
One comprehensive systematic review exploring efficacy of different pharmacological treatments on non-specific fatigue in palliative care included 10 studies investigating amantadine (n = 6), pemoline, and modafinil in pwMS (33). The authors reported mixed results with weak and inconclusive data. Amantadine (total n = 6) was found to demonstrate some improvement in fatigue in pwMS (meta-analysis of three-studies; standard mean difference compared to placebo 1.68). Both pemoline (n = 3) and modafinil (n = 2) failed to demonstrate a significant effect for management of fatigue in pwMS (33).
Commonly used pharmacological agents for fatigue and MS are summarized in Table 3, along with indications, doses, and side effects.
Different pharmacological agents used for treatment of fatigue in pwMS include Amantadine, Modafinil, and Pemoline. There is however, insufficient research-derived evidence to support these pharmacological agents for management of MS related fatigue.
Evidence for Non-Pharmacological Interventions for Fatigue in Persons with MS
There is widespread agreement in the literature that, due to the complex, multidimensional, and highly subjective nature of MS-related fatigue, comprehensive goal orientated management programs that incorporate multi-disciplinary (MD) expertise are required, and patients need to be evaluated regularly through appropriate clinical outcome measures (17, 18). The characteristics of the all included studies evaluating non-pharmacological interventions for fatigue in pwMS are summarized in Table 4.
Multi-Disciplinary Rehabilitation (Level I Evidence)
Existing clinical practice guidelines for MS recommend comprehensive, co-ordinated MD care, including symptomatic management, and appropriate follow up, education, and support for patients and carers (26). MD rehabilitation, a co-ordinated delivery of patient-centered, time-based, functionally oriented intervention/s by two or more disciplines (such as physiotherapy, occupational therapy, social work, psychology, and other allied health, nursing), under medical supervision (17), should be the best approach in symptomatic management in MS, including fatigue (5, 34). A systematic review of MD rehabilitation in MS (17), found a “strong evidence” to support MD rehabilitation in producing short-term gains at the levels of activity (disability) and participation in patients with MS. Of the 10 included trials, fatigue was considered in only two studies evaluating outpatient and home-based rehabilitation programs. A CCT (35) evaluating the influence of an extended MD outpatient rehabilitation found that fatigue symptoms were significantly reduced in the treatment group compared to the control group at 1-year follow-up (p = 0.004). Similar result was reported in another RCT evaluating impact of outpatient MD rehabilitation. The authors reported that a 12-week rehabilitation program significantly reduced fatigue and improved social functioning and depression (p < 0.001) (36). There was no convincing evidence regarding the effectiveness of inpatient MD rehabilitation programs for management of fatigue (17). An RCT investigating MD inpatient rehabilitation did not find any significant benefits of such a program on disability level or perceived fatigue (37).
Specific Rehabilitation Interventions
The cause and effect of fatigue are considered to be multidimensional and its impact extends from general everyday activity to overall QoL of pwMS (11, 38). Improving or restoring physical and psychosocial abilities and education have been proposed to counteract many MS-fatigue-related consequences. A rehabilitation approach to fatigue management in pwMS includes a spectrum of interventions, which have been examined in several published reviews. However, many of these interventions have not yet been included routinely in comprehensive MD rehabilitation programs, and few studies show their implementation. The existing evidence for various specific rehabilitation interventions for fatigue management in pwMS is summarized below.
Physical Therapeutic Modalities
Physical therapeutic modalities are considered to be one of the most efficient strategies in rehabilitation of MS patients in improving or restoring physical abilities. However, its role in MS-related fatigue management has been controversial. In past years, pwMS were advised not to participate in physical activities because it was believed to lead to worsening of symptoms or fatigue (15, 39, 40). However, recent studies on exercise therapy in MS have demonstrated that it results in substantial long-term reduction in functional limitations and enhanced QoL, and have the potential to reduce fatigue in pwMS (39).
Exercise (Level I)
Exercise therapy is a core rehabilitative measure, which aims to improve motor functions (such as co-ordination, fine-movements), balance, gait, and reduction of MS-related symptoms. Compared with the other interventions, exercise has been more frequently investigated for MS-related fatigue, which has resulted in several systematic reviews/meta-analyses evaluating various exercise modalities for the management of fatigue (11, 41–45). A wide range of exercise interventions were investigated, which included resistance training, endurance training, aquatic exercises, leisure activities, and a combination of two or more exercise modalities. In a recently published systematic review, Asano and Finlayson reported strong evidence for exercise-based rehabilitation in terms of reducing severity of patient-reported fatigue (11). Although there was heterogeneity among the included trials (n = 10 studies; p = 0.003), exercise interventions were still found to have a significant beneficial effect in managing fatigue in pwMS (pooled ES was 0.57; 95% CI: 0.10–1.04, p = 0.02). The authors stated that the extent of the intervention effects varied considerably and only a certain group of patients (younger, with stable MS) appear to experience benefit. For other MS subgroups, such as older adults or those with progressive MS and/or severe disability, there was no evidence of benefit. Further, it was not possible to identify which types or components or intensity of exercise achieved benefits for fatigue management. Another meta-analysis (n = 17 RCTs), demonstrated a similar positive effect of exercise interventions for MS-related fatigue (45). The authors showed that exercise training was associated with a significant reduction in fatigue among pwMS (weighted mean ES = 0.45; 95% CI = 0.22–0.68, p ≤ 0.001) (45). A systematic review by Andreasen et al. assessed the beneficial effect of different exercise categories separately; these included endurance training, resistance training, combined, or “other” training modalities (39). The authors, consistent with other reviews, found marked heterogeneity among the trials, as only a few studies evaluated MS fatigue as the primary outcome and many studies included non-fatigued MS patients. Overall, all type of exercise interventions were shown to have the potential to reduce MS fatigue (39). The authors concluded that, compared to other exercise modalities, endurance training was studied more frequently (n = 11 studies) and showed more consistent positive effects (39).
Several reviews evaluated exercise therapy for MS in general (42, 44, 46) and reported strong evidence in favor of exercise therapy compared to no exercise therapy, in terms of muscle power, exercise tolerance, and mobility-related activities. Conversely, subgroup analysis of results on fatigue showed mixed results. One study found that neurophysiologically based physiotherapy or a combined training program (physiotherapy plus aerobic training) were associated with significant improvement in impairment and fatigue (47).
Overall, the evidence regarding exercise modalities for MS-related fatigue was inconsistent and data for an optimal type or intensity of exercise intervention are still insufficient. Some types of exercise interventions which include endurance and a resistance-training component may have potential beneficial effects on fatigue reduction in pwMS.
Aquatic Therapy (Level II)
Few studies have evaluated aquatic therapy, which aims to reduce resistance of movements and gravity by exercising in water (pool therapy, hydrotherapy, balneotherapy), for management of fatigue in pwMS (48–52). There is evidence from two RCTs showing beneficial effects of an aquatic exercise program for MS-related fatigue. One RCT examined the effectiveness of a supervised 8-week aquatic exercise training program (60 min session, three times a week) on fatigue and health-related QoL in women (n = 32) with MS (50). The participants in the aquatic exercise group showed significant improvements in fatigue and QoL after 4 and 8 weeks compared with the control group (50). Another RCT (n = 73) suggested that a structured aquatic exercise (Ai Chi) program for 20 weeks (40 sessions) improved fatigue, pain, spasms, disability, and depression in pwMS (48). Bayraktar et al. investigated the effects of a similar aquatic exercise program (Ai Chi) in a CCT (n = 23) on balance, functional mobility, strength, and fatigue in ambulatory pwMS (53). The authors reported significant improvements in fatigue, static standing balance, functional mobility, and upper and lower extremity muscle strength in the treatment group (p < 0.05) (53).
Aquatic exercise training can improve fatigue and other MS-related symptoms, function and quality of life of pwMS and could be considered for inclusion in management programs.
Tai Chi (Level II)
Tai Chi is gaining momentum in rehabilitation settings and can improve balance, posture, muscle strength, psychological issues (stress reduction, and decreased anxiety, depression and mood disturbance) and general well-being in people with various medical conditions (54, 55). The effects of Tai Chi on fatigue in pwMS have been evaluated in only a few studies. Two trials (one RCT and one CCT) (also reported under aquatic exercise) investigated the effectiveness of Tai Chi aquatic exercise program in reducing symptoms, including fatigue and improving physical function in pwMS (48, 53). There was a significant reduction in fatigue in individuals with MS participating in the Tai Chi classes as compared to the control group (see above in section “Aquatic Therapy”). Another comparative study found that practicing Tai Chi for 2 months daily was associated with some improvements in fatigue and significant improvements in balance and depressive symptoms in pwMS (56).
There is limited evidence suggesting the effectiveness of Tai chi in improving fatigue symptoms in pwMS. Further studies with a larger sample size are needed to confirm the potential effectiveness of Tai chi in fatigue management in pwMS.
Cooling Therapy (Level II)
Physiological approaches such as cooling techniques using different cooling temperatures and durations have been tested for symptomatic management in heat-sensitive pwMS. Beenakker et al. conducted a RCT showing a beneficial effect of cooling therapy in reducing fatigue, improving postural stability, and muscle strength in pwMS when wearing a cold vest with active cooling (7°C, 60 min) (57). Another study investigating the effects of immersing participants’ lower body regions in water baths at 16–17°C for 30 min before training, found that fatigability significantly reduced in these patients during training sessions (58). These effects of cooling on functional improvements are most probably due to temperature-induced changes (Uhthoff phenomenon) in central motor conduction in demyelinated fibers (59).
Pre-cooling or cooling during and after therapy may decrease fatigue and increase the effect of active physical training in thermo sensitive pwMS. However, the evidence is limited and unclear. Further research is required to identify who will benefit from these techniques.
Pulsed Electro-Magnetic Devices (Level II)
Low-level pulsed electro-magnetic field devices have been investigated in a few trials and have shown positive effects in reducing for MS-related fatigue (60–62). A multi-center RCT (n = 117) found that wearing an active low-level, pulsed electro-magnetic field device on one or more acupressure points daily for up to 4–8 weeks, significantly decreased fatigue (60). Similar positive results were reported in another RCT (n = 33) conducted earlier using the similar device (61). The clinical effects in these trials were small and long-term follow-up data were lacking.
Exposure to pulsing, weak electromagnetic fields can alleviate fatigue symptoms in pwMS, however, additional research is needed into the feasibility and long-term use of these devices, due to limited access and cost of devices.
Behavioral and Educational Interventions
Several published reviews and studies have examined the effectiveness of various types of behavioral and/or educational interventions for management of fatigue in pwMS, which included group fatigue management programs, energy conservation programs, and psychotherapies [e.g., cognitive behavioral therapy (CBT) and mindfulness-based intervention]. A meta-analysis investigated overall effectiveness of different types of educational programs on reducing the impact or severity of self-reported fatigue in pwMS (11). The authors included eight RCTs, involving 662 pwMS. Educational interventions included a fatigue management program, energy conservation programs, mindfulness interventions, and CBT. The authors found significant global improvement with a large pooled treatment ES for the educational interventions of 0.54 (95% CI: 0.30–0.77 p < 0.001; range: −0.16 to 1.11) (11).
Fatigue Management Programs (Level II)
A number of structured fatigue management programs have been explored in pwMS and most appeared effective in reducing fatigue. A multi-centered parallel arm RCT (n = 164) evaluated the effectiveness of a group-based program for managing MS-fatigue [fatigue: applying cognitive behavioral and energy effectiveness techniques to lifestyle (FACETS)], which was based upon a conceptual framework integrating elements from cognitive behavioral, social-cognitive, energy effectiveness, self-management, and self-efficacy theories (62). The program consisted of interactive group sessions and activities (90-min sessions weekly for 6 weeks) and was facilitated by two health professionals (such as occupational therapists, nurses, or physiotherapists). The authors found significant differences favoring the intervention group on fatigue self-efficacy at 1 month follow-up (mean difference = 9; 95% CI 4–14) with a large ES (ES = 0.54, p = 0.001). At 4 months follow-up, the positive effects of the program still remained significant with a moderate ES (ES = 0.36; p = 0.05; mean difference = 6; 95% CI 0–12). In addition, significant improvement in fatigue severity was also found in the intervention group (p = 0.01) at 4 months follow-up (62). In a 1-year follow-up study by the same authors, the findings showed that the benefits of the FACETS program for fatigue severity and self-efficacy were mostly sustained, with a slight reduction in standardized ESs (ES = −0.29, p = 0.06 and 0.34, p = 0.09, respectively) with additional significant improvements in QoL (p = 0.046) (63). Another RCT (n = 51) evaluating the efficacy of a MD fatigue management program in pwMS, however, showed no efficacy in reducing the impact of fatigue compared to a placebo intervention program (34). The MD fatigue management program comprised interactive educational sessions about possible strategies to manage fatigue and reduced energy levels (2 h sessions weekly for 4 weeks).
A structured fatigue management program based on psychological approaches delivered by health professionals can be effective in reducing fatigue severity and increasing fatigue self-efficacy for pwMS. It can be clinically beneficial and can be readily incorporated into existing services.
Energy Conservation Interventions (Level I)
A systematic review evaluated the effectiveness of energy conservation treatment for fatigue and QoL in pwMS (64). The authors included six trials (four RCTs and two CCTs) involving 494 participants, which evaluated different energy conservation interventions based on evidence-based protocols, which included education about balancing, modifying and prioritizing activities, rest, self-care, effective communication, biomechanics, ergonomics, and environmental modification. The results were mixed due to heterogeneity among the included studies. Meta-analysis of two high-quality studies showed that energy conservation interventions treatment was significantly more effective than no treatment (waiting controls) in reducing the impact of fatigue and in improving QoL in the short-term. This was further supported by the qualitative best-evidence synthesis of the other studies showing moderate to strong evidence (64). There was no evidence that MD fatigue management programs were more effective than placebo for any fatigue-related outcome.
Energy conservation interventions can be effective in reducing the impact of fatigue and improving QoL in pwMS in the short-term. More high-quality RCTs are still needed to investigate the usefulness of these treatments in the longer-term.
Mindfulness-Based Interventions (Level I)
Mindfulness-based interventions have become increasingly popular in various areas of chronic disease management such as depression, stroke, chronic pain, etc. (65). Mindfulness-based interventions include a wide range of interventions, such as meditation, relaxation, and breathing techniques, yoga, Tai Chi, hypnosis, visual imagery, and spirituality (55). There are few studies evaluating the effects of the mindfulness-based approach in alleviating fatigue in pwMS. A recently published systematic review of mindfulness-based interventions found only three trials (two RCTs and one CCT) involving 183 participants (65). All trials emphasized on mindful breath awareness, mindful movement, and body awareness or “scanning.” All three studies measured the effect of intervention on fatigue and found a significantly beneficial effect of intervention on fatigue scores. One included RCT found a significant post-intervention reduction in fatigue in both the overall population and in subgroup analyses of those with pre-intervention impairment. This beneficial effect was maintained at 6 months (65).
Mindfulness-based interventions can be beneficial for fatigue management in pwMS and are conceptually appealing. These interventions could be considered in a patient management plan.
Cognitive and Psychological Interventions (Level II)
Several studies have investigated cognitive training in pwMS aiming mainly to improve attentional deficits, communication, and memory (66). Overall evidence for beneficial effects of psychological interventions in management of fatigue in pwMS is scarce. A systematic review reported that cognitive behavioral approaches were beneficial in the treatment of depression and in helping people adjust to, and cope with having MS (66). However, the authors did not find any studies focusing on psychological approaches to managing fatigue in pwMS. Findings from a few studies evaluating fatigue as a secondary outcome showed inconclusive and/or non-significant improvements in fatigue management (66).
A recent RCT (n = 40) showed that an internet-based cognitive behavior therapy (CBT) program – “MS Invigor8” was an effective treatment for MS-related fatigue (67). The CBT included eight tailored, interactive sessions with a clinical psychologist over 8–10 weeks. The treatment group reported significantly greater improvements in fatigue severity and impact as well as in anxiety, depression and quality-adjusted life years (67). Another RCT (n = 72) showed significantly greater improvements in fatigue in pwMS after eight weekly sessions of CBT (p < 0.02) compared to relaxation therapy (68). However, both groups showed clinically significant decreases in fatigue. ESs for reduction in fatigue from baseline to the end of treatment were 3.03 (95% CI 2.22–3.68) for the CBT group across the 8 months compared with the relaxation therapy group (ES 1.83; 95% CI 1.26–2.34) (68).
Psychological interventions, particularly CBT, can be a clinically and cost-effective treatment for MS fatigue. There has been a growing interest in these interventions as a means of empowering patients, improving symptoms and overall quality of life. Additional studies are warranted, particularly those that include larger numbers of people and longer term follow-up.
Fatigue, a multidimensional, complex, and highly subjective symptom, is one of the most frequent symptoms of MS patients. It is associated with several factors or mechanisms. There is a continuing need for a comprehensive, multi-disciplinary long-term management, which includes both pharmacological and non-pharmacological interventions. This systematic review provides an evidence-based overview of the effectiveness of different interventions (pharmacological and non-pharmacological) currently used to alleviate fatigue in pwMS. It highlights the lack of, methodologically robust trials to evaluate effectiveness of MS fatigue management interventions.
Despite many interventions (both pharmacological and non-pharmacological) used for the management of fatigue in pwMS, effects of these vary considerably and any beneficial effect was at best modest and/or is yet to be established. Non-pharmacological interventions (both exercise and psychological/educational interventions) appear to have a stronger and more significant favorable effect on reducing the impact or severity of fatigue compared to commonly prescribed pharmacological agents.
In conclusion, there is increasing awareness of the role of both pharmacological and non-pharmacological interventions in early and long-term management of fatigue in pwMS. Although this review highlights the lack of high-quality studies evaluating fatigue management strategies in pwMS (types, settings, components, modalities, and duration of therapy), it adds to the existing evidence by providing structured pre-defined “level of evidence” to support different interventions for the management of fatigue in this population. The findings from this review suggest that non-pharmacological approaches used in isolation and/or in combination with pharmacological agents should be the mainstay of management of fatigue in pwMS. Further studies across the broad range of interventions for the management of fatigue in MS are warranted, using high-quality research approaches.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
2. MS Society Australia. MS Practice – for Health Professionals. (2014). Available from: www.msaustralia.org.au
4. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis. Washington DC: Paralyzed Veterans of America (1998).
5. Kos D, Kerckhofs E, Nagels G, D’Hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair (2008) 22(1):91–100. doi: 10.1177/1545968306298934
7. Neumann M, Sterr A, Claros-Salinas D, Gütler R, Ulrich R, Dettmers C. Modulation of alertness by sustained cognitive demand in MS as surrogate measure of fatigue and fatigability. J Neurol Sci (2014) 340(1–2):178–82. doi:10.1016/j.jns.2014.03.024
11. Asano M, Finlayson M. Meta-analysis of three different types of fatigue management interventions for people with Multiple Sclerosis: exercise, education, and medication. Mult Scler Int (2014) 2014:798285. doi:10.1155/2014/798285
13. Krause I, Kern S, Horntrich A, Ziemssen T. Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. Mult Scler (2013) 19(13):1792–9. doi:10.1177/1352458513485655
14. Khan F, Pallant JF, Brand C, Kilpatrick TJ. Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry (2008) 79(11):1230–5. doi:10.1136/jnnp.2007.133777
19. Khan F, Amatya B, Ytterberg C, Johansson S, Kesselring J. Content comparison of multidimensional, patient-reported outcome measures in multiple sclerosis rehabilitation and the International Classification of Functioning, Disability and Health (ICF): a systematic review. Neurodegen Dis Manag (2013) 3(6):549–64. doi:10.2217/nmt.13.57
22. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis (1994) 18(Suppl 1):S79–83. doi:10.1093/clinids/18.Supplement_1.S79
24. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol (1989) 46(10):1121–3. doi:10.1001/archneur.1989.00520460115022
25. Penner IK, Raselli C, Stöcklin M, Opwis K, Kappos L, Calabrese P. The fatigue scale for motor and cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 15(12):1509–17. doi:10.1177/1352458509348519
26. National Institute for Clinical Excellence (NICE). Management of Multiple Sclerosis in Primary and Secondary Care. Clinical Guidelines 8. London: National Institute for Clinical Excellence (2003).
27. National Health and Medical Research Council (NHMRC). NHMRC Additional Levels of Evidence and Grades for Recommendations for Developers of Guidelines. (2009). Available from: https://www.nhmrc.gov.au/_files_nhmrc/file/guidelines/developers/nhmrc_levels_grades_evidence_120423.pdf
28. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology (1995) 45(11):1956–61. doi:10.1212/WNL.45.11.1956
29. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology (1992) 42(8):1468–71. doi:10.1212/WNL.42.8.1468
33. Peuckmann V, Elsner F, Krumm N, Trottenberg P, Radbruch L. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev (2010) 11:CD006788. doi:10.1002/14651858.CD006788.pub2
34. Kos D, Duportail M, D’Hooghe M, Nagels G, Kerckhofs E. Multidisciplinary fatigue management programme in multiple sclerosis: a randomized clinical trial. Mult Scler (2007) 13(8):996–1003. doi:10.1177/1352458507078392
35. Di Fabio RP, Soderberg J, Choi T, Hansen CR, Schapiro RT. Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. Arch Phys Med Rehabil (1998) 79(2):141–6. doi:10.1016/S0003-9993(98)90290-8
36. Patti F, Ciancio MR, Reggio E, Lopes R, Palermo F, Cacopardo M, et al. The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol (2002) 249(8):1027–33. doi:10.1007/s00415-002-0778-1
38. Motl RW, McAuley E. Symptom cluster as a predictor of physical activity in multiple sclerosis: preliminary evidence. J Pain Symptom Manage (2009) 38(2):270–80. doi:10.1016/j.jpainsymman.2008.08.004
40. Sabapathy NM, Minahan CL, Turner GT, Broadley SA. Comparing endurance- and resistance-exercise training in people with multiple sclerosis: a randomized pilot study. Clin Rehabil (2011) 25(1):14–24. doi:10.1177/0269215510375908
42. Latimer-Cheung AE, Pilutti LA, Hicks AL, Martin Ginis KA, Fenuta AM, MacKibbon KA, et al. Effects of exercise training on fitness, mobility, fatigue, and health-related quality of life among adults with multiple sclerosis: a systematic review to inform guideline development. Arch Phys Med Rehabil (2013) 94(9):1800e–28e. doi:10.1016/j.apmr.2013.04.020
43. Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs (2006) 56(6):617–35. doi:10.1111/j.1365-2648.2006.04054.x
45. Pilutti LA, Greenlee TA, Motl RW, Nickrent MS, Petruzzello SJ. Effects of exercise training on fatigue in multiple sclerosis: a meta-analysis. Psychosom Med (2013) 75(6):575–80. doi:10.1097/PSY.0b013e31829b4525
47. Rasova K, Havrdova E, Brandejsky P, Zálisová M, Foubikova B, Martinkova P. Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis. Mult Scler (2006) 12(2):227–34. doi:10.1191/135248506ms1248oa
48. Castro-Sánchez AM, Matarán-Peñarrocha GA, Lara-Palomo I, Saavedra-Hernández M, Arroyo-Morales M, Moreno-Lorenzo C. Hydrotherapy for the treatment of pain in people with multiple sclerosis: a randomized controlled trial. Evid Based Complement Alternat Med (2012) 2012:473963. doi:10.1155/2012/473963
50. Kargarfard M, Etemadifar M, Baker P, Mehrabi M, Hayatbakhsh R. Effect of aquatic exercise training on fatigue and health-related quality of life in patients with multiple sclerosis. Arch Phys Med Rehabil (2012) 93(10):1701–8. doi:10.1016/j.apmr.2012.05.006
51. Pariser G, Madras D, Weiss E. Outcomes of an aquatic exercise program including aerobic capacity, lactate threshold, and fatigue in two individuals with multiple sclerosis. J Neurol Phys Ther (2006) 30(2):82–90. doi:10.1097/01.NPT.0000282572.63297.3d
52. Salem Y, Scott AH, Karpatkin H, Concert G, Haller L, Kaminsky E, et al. Community-based group aquatic programme for individuals with multiple sclerosis: a pilot study. Disabil Rehabil (2011) 33(9):720–8. doi:10.3109/09638288.2010.507855
53. Bayraktar D, Guclu-Gunduz A, Yazici G, Lambeck J, Batur-Caglayan HZ, Irkec C, et al. Effects of Ai-Chi on balance, functional mobility, strength and fatigue in patients with multiple sclerosis: a pilot study. NeuroRehabilitation (2013) 33(3):431–7. doi:10.3233/NRE-130974
57. Beenakker EA, Oparina TI, Hartgring A, Teelken A, Arutjunyan AV, De Keyser J. Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production. Neurology (2001) 57(5):892–4. doi:10.1212/WNL.57.5.892
59. Humm AM, Beer S, Kool J, Magistris MR, Kesselring J, Rösler KM. Quantification of Uhthoff’s phenomenon in multiple sclerosis: a magnetic stimulation study. Clin Neurophysiol (2004) 115(11):2493–501. doi:10.1016/j.clinph.2004.06.010
60. Lappin MS, Lawrie FW, Richards TL, Kramer ED. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial. Altern Ther Health Med (2003) 9(4):38–48.
61. Richards TL, Lappin MS, Acosta-Urquidi J, Kraft GH, Heide AC, Lawrie FW, et al. Double-blind study of pulsing magnetic field effects on multiple sclerosis. J Altern Complement Med (1997) 3(1):21–9. doi:10.1089/acm.1997.3.21
63. Thomas PW, Thomas S, Kersten P, Jones R, Nock A, Slingsby V, et al. Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis. BMC Neurol (2010) 10:43. doi:10.1186/1471-2377-10-43
64. Thomas PW, Thomas S, Kersten P, Jones R, Slingsby V, Nock A, et al. One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. BMC Neurol (2014) 14(1):109. doi:10.1186/1471-2377-14-109
65. Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil (2013) 94(7):1360–76. doi:10.1016/j.apmr.2013.01.025
68. Moss-Morris R, McCrone P, Yardley L, van Kessel K, Wills G, Dennison L. A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue. Behav Res Ther (2012) 50(6):415–21. doi:10.1016/j.brat.2012.03.001
69. van Kessel K, Moss-Morris R, Willoughby E, Chalder T, Johnson MH, Robinson E. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med (2008) 70(2):205–13. doi:10.1097/PSY.0b013e3181643065
70. Thomas S, Thomas PW, Kersten P, Jones R, Green C, Nock A, et al. A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psychiatry. (2013) 84(10):1092–9. doi:10.1136/jnnp-2012-303816
Keywords: multiple sclerosis, fatigue, disability, rehabilitation outcomes, symptomatic treatment
Citation: Khan F, Amatya B and Galea M (2014) Management of fatigue in persons with multiple sclerosis. Front. Neurol. 5:177. doi: 10.3389/fneur.2014.00177
Received: 18 July 2014; Paper pending published: 26 August 2014;
Accepted: 01 September 2014; Published online: 15 September 2014.
Edited by:Christian Dettmers, Kliniken Schmieder Konstanz, Germany
Reviewed by:Thomas Henze, Reha Zentrum Nittenau, Germany
Claude Vaney, Berner Klinik Montana, Switzerland
Copyright: © 2014 Khan, Amatya and Galea. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Fary Khan, Department of Rehabilitation Medicine, Royal Melbourne Hospital, Poplar Road, Parkville, Melbourne, VIC 3052, Australia e-mail: email@example.com